Skip to main content

Table 1 (abstract O07). Assessment of drug response in the patients with colchicine resistant familial Mediterranean fever

From: Abstracts from the ISSAID 2021 Periodic Congress

  Baseline
(n=114)
1st month
(n=114)
3rd month
(n=114)
6th month
(n=114)
12th month
(n=114)
18th month
(n=114)
24th month
(n=114)
PGA* 8 (5-10) 1 (0-10) 0 (0-5) 0 (0-5) 0 (0-3) 0 (0-5) 0 (0-3)
CRP* 16.2 (11-31) 0.65 (0.02-58.6) 0.2 (0-15.8) 0.7 (0-68) 0.5 (0-24.9) 0.3 (0-41) 0.3 (0.16.1)
SAA* 89 (2.9-1870) 3.9 (0-17) 4 (0-23) 3.3 (0-70) 3.6 (0-152) 3 (0-42) 3 (0-24)
Dose interval of CAN (weeks) 4 (4-8)
4 weeks in 94
8 weeks in 20
4 (4-8)
4 weeks in 94
8 weeks in 20
4 (4-8)
4 weeks in 94
8 weeks in 20
6 (4-8)
4 weeks in 66
6 weeks in 21
8 weeks in 27
6 (4-8)
4 weeks in 50
6 weeks in 21
8 weeks in 41
12 weeks in 2
8 (4-12)
4 weeks in 45
6 weeks in 21
8 weeks in 40
12 weeks in 3
No drug in 5
8 (4-12)
4 weeks in 39
6 weeks in 25
8 weeks in 38
No drug in 12
Dosage of CAN (mg/kg) 2-4 mg/kg 2-4 mg/kg 2-4 mg/kg 2-4 mg/kg 2-4 mg/kg 2-4 mg/kg 2-4 mg/kg
Number of patients experienced attacks NA 0 2 1 5 4 2
Number of patients requiring higher dose or shortening drug interval NA 0 2
(recurrent attacks)
0 2 (recurrent attacks) 4 (recurrent attacks)
(shortened from 8  to 6 weeks
2 (recurrent attacks, CAN was restarted)
Number of patients whose prolonged drug interval NA 0 7 patients
(prolonged from 4 to 8 weeks)
21 patients
(prolonged from 4 to 6 weeks)
16 patients
(prolonged from 4 to 8 weeks)
2 patients (prolonged from 8 to 12 weeks)
5 patients (prolonged from 4 to 8 weeks)
1 patient (prolonged from 8 to 12 weeks)
6 patients
(prolonged from 4 to 8 weeks)
NA
Number of patients discontinued CAN 0 0 0 0 5 patients 7 patients 0
Number of infections NA 1 (pneumonia) 1 (upper respiratory tract infection) 0 0 0 2 (upper respiratory tract infection)
Number of adverse event NA 0 0 0 0 0 0